An observational study in Hemophilia A, Hemophilia B and Von Willebrand Diseases, sponsored by World Federation of Hemophilia. Recruiting at 1 site in Canada. Per ClinicalTrials.gov, last updated 2023-08-14.
Sponsored by World Federation of Hemophilia · Observational
Among 106 studies in Hemophilia A with a site in Canada — 16 open to participants now, 28 under way, 15 of them phase 3. Hemophilia A · Canada.
Among the 106 studies in Hemophilia A with a site in Canada, this one has the largest planned enrollment of the 33 observational ones that give a count, is one of 12 that started in 2018, is one of 33 observational ones, reaches primary completion later than 15 of the 27 other live ones, and was the 54th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →16 of the 106 studies in Hemophilia A with a site in Canada are open now. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Canada, United States, Argentina and 15 more countries
Ages 18+
Bayer · Sites in Canada, United States, Brazil and 8 more countries
Ages 7–12
Hoffmann-La Roche · Sites in Canada, United States, Argentina and 19 more countries
Ages 12+
Sanofi · Sites in Canada, United States, Belgium and 9 more countries
Ages 1–11 · Men only
Sanofi · Sites in Canada, United States, Australia and 2 more countries
Ages 12+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 86 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 30 (35%) stop at 75 or younger; 54 take children under 18; 10 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 17 · Phase 3 52 · Phase 4 7
First in 1997; this study’s year is marked. 12 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20,000 is above the median of 81 across 310 observational studies indexed under Hemophilia A.
Median enrollment 73 across the 73 interventional studies, 190 across the 33 observational. Of the 74 that completed or were terminated, 40 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 106 have an industry lead sponsor. The 10 most frequent:
World Federation of Hemophilia is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
World Federation of Hemophilia has 3 studies filed under Hemophilia A — fewer than ten, so there is no comparison to draw.
7 of the studies in Hemophilia A with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04644575Phase 3Bioverativ, a Sanofi companyLong-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A | 2027-01-15 |
| NCT05662319Phase 3SanofiA Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia | 2027-03-25 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT05181618Hoffmann-La RocheA Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis | 2026-11-19 |
| NCT03932201BayerEvaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 106 studies in Hemophilia A with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The WBDR is an international observational disease registry of patients with hemophilia. It will provide a platform for a network of hemophilia treatment centres (HTCs) around the world to collect uniform and standardized patient data and guide clinical practice. With informed consent from the patient, the WBDR stores anonymous data about the person's disease, such as hemophilia type and severity, symptoms, and treatment.
The WBDR is a prospective, global registry of patients diagnosed with hemophilia A and B. Following the success of a pilot study, implementation of the full scale WBDR is underway. The goals are to enroll at least 200 HTCs from more than 50 countries, and at least 10,000 people with hemophilia, during the first five years, aiming for representation of patients from around the world and from all levels of access to care. Minimal criteria for participation of HTCs include access to reliable internet, human resources for data entry and commitment to long-term enrolment and follow-up of patients. The WBDR database is being developed through a collaboration between the WFH, Karolinska Institute and Health Solutions.
By combining data from countries around the world, the WBDR will provide a large amount of real world data, on which researchers can address important scientific and clinical issues. The World Bleeding Disorders Registry (WBDR) is intended to fill existing gaps in knowledge by collecting real world data on the patient clinical experience around the globe.
Patients of participating Hemophilia Treatment Centres with Hemophilia A or B, or von Willebrand Disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Number of participants recruited
Time frame: 5 years
Number of participating Hemophilia Treatment Centres
Time frame: 5 years
Number of participating countries
Time frame: 5 years
Started Jan 2018 (actual). Primary completion is estimated for Jan 2028, 120 months after the start.
Of 78 non-industry observational studies under Hemophilia A, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 96. This study's planned 120 months is above that.
Counting every sponsor, half of 131 studies reached it within 45 months; a quarter within 25 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
World Federation of Hemophilia